Medeon Biodesign

Medeon Biodesign Co., Ltd. (Stock code: 6499.TW)  was jointly founded by Dr. Yueteh Jang, a renowned medical device expert, along with Centerlab Group and Shangzhi LifeTech Ventures, a subsidiary of YFY Group. The company focuses on advanced medical device development in Taiwan. Leveraging Dr. Jang's expertise and global medical resources, Medeon specializes in Class II and III medical devices, excelling in areas like cardiovascular surgery, urology, orthopedics, and laparoscopy. Recently, Medeon expanded into Contract Development and Manufacturing Organization (CDMO) services through Medeologix, uniting U.S. and Taiwan production to provide a seamlessly integrated solution for global medical giants.

Investment time	2012
Incubation Successes	Center Ventures assisted Dr. Yue-Teh Jang in establishing Medeon Biodesign with the goal of retaining world-class talents in Taiwan and advancing the biotechnology industry. Through providing executive management knowledge, experience sharing, and consulting platform, Center Ventures accelerates integration with local capital markets and resources to support Medeon Biodesign’s innovative business model, which is the R&D and licensing of high-end medical device. Center Ventures fully supports Medeon Biodesign mirroring its success and becoming an incubator platform for Taiwan’s high-end innovative medical devices.
Milestones	Medeon Biodesign was publicly listed on Taipei Exchange in 2016 (Stock Code: 6499). Medeon Biodesign entered into a definitive asset purchase agreement with Tokyo-based Terumo Corporation for its large bore vascular closure system XPro™ System (IVC-C01). The transaction consists of an up-front payment of US$20 million and milestone payments.